米拉贝隆减少前列腺癌125I近距离放疗后3个月排尿频率并改善膀胱过度活动症症状:一项开放标签、随机、非安慰剂对照研究
本研究纳入接受125I近距离放疗的前列腺癌(cT1-cT3aN0M0)患者,随机分为坦索罗辛联合米拉贝隆组与坦索罗辛单药组。主要终点每次排尿平均尿量变化两组无显著差异(P=.17);联合组膀胱过度活动症症状评分改善更温和(P=.02),24小时排尿频率更低(P=.03)。结论:联合治疗未改善每次排尿尿量,但可改善尿频和膀胱过度活动症症状。
要点
- 坦索罗辛联合米拉贝隆组与坦索罗辛单药组每次排尿平均尿量变化无显著差异(P=.17)。
- 联合组膀胱过度活动症症状评分改善更温和(P=.02),24小时排尿频率更低(P=.03)。
- 两组3个月内尿潴留率分别为7.3%(9/122)与6.0%(7/118),无显著差异(P=.80)。
核心结论
- 125I近距离放疗后坦索罗辛联合米拉贝隆治疗与坦索罗辛单药治疗相比未改善每次排尿尿量,但可改善尿频和膀胱过度活动症症状。
研究设计与样本
- 开放标签、随机、非安慰剂对照、平行组研究,单中心纳入2016年9月至2018年10月接受125I近距离放疗的前列腺癌(cT1-cT3aN0M0)患者。
- 患者按1:1随机分为联合组(坦索罗辛0.2 mg/日联合米拉贝隆50 mg/日)或坦索罗辛单药组,采用信封法随机。
- 主要终点为125I近距离放疗后3个月每次排尿平均尿量较基线的变化。
主要发现
- 联合组(n=108)与坦索罗辛单药组(n=110)每次排尿尿量平均变化分别为-62.5(标准差±53.8)与-68.0(标准差±52.7)(P=.17)。
- 联合组膀胱过度活动症症状评分改善较坦索罗辛单药组更温和(P=.02)。
- 联合组24小时排尿频率较坦索罗辛单药组更低(P=.03)。
- 米拉贝隆组与坦索罗辛单药组3个月内尿潴留率分别为7.3%(9/122)与6.0%(7/118)(P=.80)。
关键数值与推荐
- 联合组每次排尿尿量平均变化-62.5(标准差±53.8),坦索罗辛单药组-68.0(标准差±52.7),P=.17。
- 联合组膀胱过度活动症症状评分改善较坦索罗辛单药组更温和,P=.02。
- 联合组24小时排尿频率较坦索罗辛单药组更低,P=.03。
- 米拉贝隆组3个月内尿潴留率7.3%(9/122),坦索罗辛单药组6.0%(7/118),P=.80。
临床怎么用
- 原文结论为联合治疗未改善每次排尿尿量,但可改善尿频和膀胱过度活动症症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the additional effects of mirabegron to alpha-1 adrenergic antagonist on lower urinary tract symptoms of patients who underwent 125I-brachytherapy for prostate cancer. PATIENTS AND METHODS: Patients who underwent 125I-brachytherapy for prostate cancer (cT1-cT3aN0M0) in a single institute between September 2016 and October 2018 were enrolled in the randomized, non-placebo, open-labeled, paralleled study. Patients were randomly distributed (1:1) to combination group (tamsulosin (0.2 mg/day) plus mirabegron (50 mg/day)) or tamsulosin-alone group after 125I -brachytherapy by envelope method. The primary endpoint was the change from baseline in mean voided volume per micturition 3 months after 125I brachytherapy. The secondary endpoints included the changes from baseline of International Prostate Symptom Score, Overactive Bladder Symptom Score, and Expanded Prostate Cancer Index Composite scores and 24 hours urinary frequency after 3 months after 125I brachytherapy. RESULTS: The mean changes in volume voided per micturition in the combination (n = 108) and tamsulosin-alone (n = 110) groups were -62.5 (standard deviation, ±53.8) and -68.0 (standard deviation, ±52.7), respectively (P = .17). The change in Overactive Bladder Symptom Score in combination group (P = .02) was more moderate than in tamsulosin-alone group; and 24 hour urinary frequency in combination group was lower (P = .03) than in tamsulosin-alone group. Retention rates within 3 months after 125I-brachytherapy in the mirabegron and tamsulosin-alone groups were 7.3% (9/122) and 6.0% (7/118), respectively (P = .80). CONCLUSION: Tamsulosin and mirabegron combination therapy after 125I-brachytherapy did not improve voided volume per micturition compared to tamsulosin-only treatment. However, it could improve frequent urination and overactive bladder symptoms.
引用
- Nakai Y, Tanaka N, Asakawa I, et al. Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labeled, Randomized, Non-Placebo-Controlled Study. Urology. 2021. PMID: 34973240. doi:10.1016/j.urology.2021.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。